Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Should Opioids Be Used Solely For Severe Pain? FDA Seeks Expert Advice

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is holding a public meeting in February to obtain information on opioid treatment for chronic pain; FDA seeks data to assess whether to restrict use and establish a maximum daily dose.

You may also be interested in...



Citizen Petition Seeks Limited Opioid Drug Indication To Curb Overuse And Abuse

Physician group appeals for FDA to rescind approval for moderate non-cancer pain and Massachusetts Democrat Rep. William Keating introduces legislation that would bar FDA approval of a non-tamper-resistant opioid drug if the same active moiety already was approved in a tamper-resistant product.

Opioid REMS Requires Sponsors To Launch Prescriber Training CME Within 9 Months

By the third year of continuing medical education efforts, FDA expects 60% of those who wrote a prescription for a long-acting/extended-release opioid in 2011 to receive training.

US FDA Heightens Focus On Cannabis With Hiring Of Norman Birenbaum As Public Health Advisor

Industry reps are glad that Birenbaum, who was the chief cannabis policy advisor to the governors of New York and Rhode Island, was given a prominent role at FDA that could spur regulatory action.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS074782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel